Canada's legalization of adult-use cannabis is just days away, October 17. In the U.S., a majority of states allow medical marijuana and eight states plus the District of Columbia permit recreational use. These numbers are likely to grow: several states have cannabis-related measures on the ballot November 6.
Marijuana sales in the U.S. are estimated to reach $8-10 billion this year and could grow to $22 billion by 2022, according to the Marijuana Business Facebook. Investors have seen explosive growth in cannabis stocks, as well as off-the-charts volatility, of which Tilray Inc. is the poster child. No wonder so many investors tread warily around the cannabis space.
An upcoming conference in New York City—the Institutional Capital & Cannabis Conference (IC3)—on October 22, will go a long way to provide information on cannabis investing. Billed as the leading investor forum for the cannabis industry, it is geared to investors who wish to "invest or learn more about this exciting and high-growth new asset class, cannabis companies and investment funds who are looking to raise money or showcase their products, and professional service providers who facilitate these groups doing business."
On the investor side, representatives from private equity companies, venture capital funds, family offices, high net worth individuals, real estate investments trusts and other real estate investment companies will be attending; the conference is open to anyone who's looking to make an investment in the sector.
The conference is geared toward investors who have minimal to no understanding and knowledge of the space, however, it will also welcome a large number of investors who are already active in the space. The keynote presentation that kicks off the one-day conference will include discussion about the state of the industry, the overall outlook, and promising growth markets in the U.S., Canada and overseas. The U.S. regulatory landscape will be discussed, as will advocacy and lobbying efforts in Washington, and how legal status is changing in some states.
Additionally, sessions will address issues such as investment opportunities in legal cannabis and will cover a number of different investment sectors in the industry, the U.S. regulatory landscape at the local, state and federal level, a comparison of the Canadian and U.S. markets, setting realistic expectations for cannabis investments, how to do due diligence on cannabis investments, lessons learned and pitfalls to be avoided from experienced investors and finance professionals, impact investing with legal cannabis, and the future of cannabis.
Major cannabis companies will be represented at the conference, including Aurora Cannabis, Canndescent, Khiron Life Sciences and Medmen, as well as companies that serve the sector, such as Kush Bottles.
Investors who are interested in attending can register here; use the code SWR for a 15% discount off the registration fee.[NLINSERT]
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an employee. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.